Correlation Between Viridian Therapeutics and Autolus Therapeutics

Can any of the company-specific risk be diversified away by investing in both Viridian Therapeutics and Autolus Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Viridian Therapeutics and Autolus Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Viridian Therapeutics and Autolus Therapeutics, you can compare the effects of market volatilities on Viridian Therapeutics and Autolus Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Viridian Therapeutics with a short position of Autolus Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Viridian Therapeutics and Autolus Therapeutics.

Diversification Opportunities for Viridian Therapeutics and Autolus Therapeutics

0.86

Correlation Coefficient

Viridian Therapeutics  Autolus Therapeutics

Very poor diversification

The 3 months correlation between Viridian and Autolus is 0.86. Overlapping area represents the amount of risk that can be diversified away by holding Viridian Therapeutics and Autolus Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Autolus Therapeutics and Viridian Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Viridian Therapeutics are associated (or correlated) with Autolus Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Autolus Therapeutics has no effect on the direction of Viridian Therapeutics i.e., Viridian Therapeutics and Autolus Therapeutics go up and down completely randomly.

Pair Corralation between Viridian Therapeutics and Autolus Therapeutics

Given the investment horizon of 90 days Viridian Therapeutics is expected to under-perform the Autolus Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Viridian Therapeutics is 1.15 times less risky than Autolus Therapeutics. The stock trades about -0.13 of its potential returns per unit of risk. The Autolus Therapeutics is currently generating about -0.09 of returns per unit of risk over similar time horizon. If you would invest  570.00  in Autolus Therapeutics on March 14, 2024 and sell it today you would lose (136.00) from holding Autolus Therapeutics or give up 23.86% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Strong
Accuracy	100.0%
Values	Daily Returns

Viridian Therapeutics  vs.  Autolus Therapeutics

Viridian Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Viridian Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's fundamental indicators remain very healthy which may send shares a bit higher in July 2024. The recent disarray may also be a sign of long period up-swing for the firm investors.

Autolus Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Autolus Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in July 2024. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Viridian Therapeutics and Autolus Therapeutics

The main advantage of trading using opposite Viridian Therapeutics and Autolus Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Viridian Therapeutics position performs unexpectedly, Autolus Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Autolus Therapeutics will offset losses from the drop in Autolus Therapeutics' long position.

The idea behind Viridian Therapeutics and Autolus Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the CEOs Directory module to screen CEOs from public companies around the world.